поздравления с юбилеем 65 лет папе от детей и внуков
Главное меню:
Интересное
поздравления с юбилеем 65 лет папе от детей и внуков, Kisqali Plus Hormone Therapy for Metastatic Breast Cancer, Metastatic Breast Cancer (mBC) Treatment | KISQALI® (ribociclib) | HCP, Metastatic Breast Cancer | KISQALI® (ribociclib), How Kisqali Works for Breast Cancer - WebMD, HIGHLIGHTS OF PRESCRIBING INFORMATION • Increased QT - Novartis, Kisqali: A First-Line Treatment Option for Breast Cancer, Frequently Asked Questions | mBC | KISQALI® (ribociclib).
If you would like to reproduce some or all of this content, see for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “A Safer, Better Treatment Option for Some Younger Women with Breast Cancer was originally published by the National Cancer Institute.”, The treatment usually shrinks tumors quickly but can have serious side effects, spurring researchers to look for less-toxic treatments. Ribociclib has become a commonly used treatment for ER-positive, HER2-negative breast cancer that requires treatment beyond surgery and radiation therapy., These tools contain useful information that can help your patients get started and stay on treatment with KISQALI. HR=hazard ratio; ITT=intent to treat; mBC=metastatic breast cancer; mOS Fasching PA, Chia S, et al. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving .
*Time spent living with breast cancer is called overall survival, or OS, in clinical trials. Median OS is the length of time when half of the people in the trial were still alive. At an 80-month check-in, median OS was 63.9 months with KISQALI + an AI vs 51.4 months with placebo + an AI., Kisqali is used to treat breast cancer that is hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative. It can be used to treat breast cancer that is advanced , receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at . high risk of recurrence . 1.2 Advanced or Metastatic Breast Cancer . KISQALI is indicated for the treatment of adults with HR -positive, HER2-negative advanced or metastatic breast cancer in . combination with:, Kisqali is a brand-name prescription drug used to treat an advanced type of breast cancer in women. It is used to treat breast cancer that has all the following properties [1]: Metastatic or locally advanced: Kisqali can treat breast cancer that is advanced (metastatic) or locally advanced. Metastatic means that the cancer has spread to , HER2 is a protein found in healthy, normal cells. A minus sign (-) after HER2 means that your cancer cells have a small amount of HER2 or none at all. HR+, HER2- is the most common subtype of breast cancer. HR+, HER2- breast cancer that is metastatic means that the cancer has spread throughout the body to a distant location., Adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with hormone receptor (HR) positive, HER2 negative advanced breast cancer, according to late breaking results of the MONALEESA-2 trial presented at the European Society for Medical Oncology (ESMO) Congress 2021.. This is the first report of a statistically significant and .